Post-severe Acute Respiratory Syndrome Coronavirus 2 Monoclonal Antibody Treatment Hospitalizations as a Sentinel for Emergence of Viral Variants in New York City

Kelsie Cowman, Yi Guo, Liise Anne Pirofski, David Wong, Hongkai Bao, Victor Chen, Una Hopkins, Erin Andrews, Joseph Hamel, Marla Keller, Eran Bellin, Raja Thota, Patricia Davis, Edwin Torres Rodriguez, Pooja Suthar, Lauren Allen, James Rossi, Adam Haviland, Erika Orner, Wendy SzymczakSadahf Shujauddin, James Mccarthy, Barbara Binder, Vanitha Pushparaj, Linda Bard, Vincent Frank Pierino, Leslie Alsina, David Esses, Alicia Mccaskie, Caron Campbell, Tabitha Madzura, Andrew Wollowitz, Kelly Basset, Deborah White, Rafael Ruiz, Frank Sosnowski, Priya Nori

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

We partnered with the US Department of Health and Human Services to treat high-risk, nonadmitted coronavirus disease 2019 (COVID-19) patients with bamlanivimab in the Bronx, New York per Emergency Use Authorization criteria. Increasing posttreatment hospitalizations were observed monthly between December 2020 and March 2021 in parallel to the emergence of severe acute respiratory syndrome coronavirus 2 variants in New York City.

Original languageEnglish (US)
Article numberofab313
JournalOpen Forum Infectious Diseases
Volume8
Issue number8
DOIs
StatePublished - Aug 1 2021

Keywords

  • Antimicrobial stewardship
  • COVID-19
  • SARS-CoV-2 variants
  • monoclonal antibodies

ASJC Scopus subject areas

  • Oncology
  • Clinical Neurology

Fingerprint

Dive into the research topics of 'Post-severe Acute Respiratory Syndrome Coronavirus 2 Monoclonal Antibody Treatment Hospitalizations as a Sentinel for Emergence of Viral Variants in New York City'. Together they form a unique fingerprint.

Cite this